A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Scabies Clinical Trial

Official title:

A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group, Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03973775
• Other study ID #: SP-2992
• Status: Completed
• Phase: Phase 3
• Start date: April 10, 2018
• Est. completion date: December 6, 2018

Study information

• Verified date: October 2020
• Source: Saptalis Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.

Description:

A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group Bioequivalence Study with Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of, Permethrin Cream 5% (Manufactured by Saptalis Pharmaceuticals, LLC) & Elimite™ (Permethrin Cream 5%, manufactured for Prestium Pharma, Inc.) in Subjects with Scabies. The objectives of this study are: Primary Objective: To establish the clinical bioequivalence of Permethrin Cream 5% (manufactured by Saptalis Pharmaceuticals, LLC) and Elimite™ (Permethrin Cream 5%, manufactured for Prestium Pharma, Inc.) in the treatment of scabies (Sarcoptes scabiei) following a single application. Secondary Objective: To compare the safety and tolerability between the study drugs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 126
• Est. completion date: December 6, 2018
• Est. primary completion date: November 13, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Months to 65 Years

Eligibility

Inclusion Criteria:

• Subjects and/or parent/guardian must have understood and signed appropriately administered informed consent/assent in their own language
• Healthy male and non-pregnant/non-lactating female subjects aged 2 months to 65 years diagnosed with scabies
• Must have dermatological evidence of active scabies (burrows, erythematous papules, etc.) confirmed by recovery of live Sarcoptes scabiei (the Principal investigator or trained and experienced Study Team examines the specimen(s) under magnification to verify the identity and viability of the scabies mite, ova, or mite feces at the site)
• The youngest subject (with scabies infestation as defined above) from each household is considered the index or primary subject of the household for evaluation of the primary endpoint. Other members of the household and close contacts are enrolled in the study as Secondary subjects and evaluated for all safety parameters (not included in primary endpoint analysis). Secondary subjects that are confirmed to have dermatological evidence of scabies should receive the same study treatment as the Index subject
• Must be available and willing to report for follow up visits
• Is otherwise healthy, well-nourished, non-febrile and not suffering from an infection likely to require systemic antibiotic or topical therapy. These criteria will be ascertained during screening by the Principal investigator
• Must agree not to use other scabicides or other medications likely to affect the evaluation of their response to scabies treatment
• If female of childbearing potential, willing to use an acceptable method of birth control, should be stable for 3 months prior to screening and throughout the study
• Must be willing to follow the procedures to decrease infestation: Clothes and bed linens that were in contact with the subjects, their household members and close contacts during the previous 48 to 72 hours will be machine washed at 60°C and machine dried the day after the first treatment. For materials that cannot be laundered, insecticide powder or aerosolized insecticide may be used, or the items may be kept in a sealed bag for at least 48 to 72 hours.

Exclusion Criteria:

• Subject or parent/guardian has not signed informed consent/assent
• Pregnant females, lactating females or females planning for a pregnancy
• Females of childbearing potential who do not agree to utilize an adequate method of contraception
• Known history of irritation or sensitivity to parasiticides
• Skin conditions that could make it difficult to evaluate the extent of an infestation or would present a problem in the evaluation of response to therapy (e.g. atopic dermatitis, eczema, contact dermatitis, lichen planus, papular urticaria, seborrheic dermatitis).
• Use within 4 weeks of baseline visit (1) immunomodulators (2) systemic medications that suppress the immune system (3) topical or oral parasiticides.
• Use within 2 weeks of baseline visit (1) topical steroids (2) topical or systemic antibiotics
• Has crusted scabies • Known allergy or hypersensitivity to permethrin, any synthetic pyrethroid or pyrethrin, plants in the Asteraceae/Compositae family (e.g. chrysanthemums, ragweed, marigolds, and daisies)
• Subjects whose household members and close contacts refuse treatment.
• Subjects with greater than 5 infested household members and close contacts
• Subjects whose sexual contacts do not agree to restrict prolonged skin to skin contact with non-household members during the study period
• Subjects with a household member less than 2 months of age
• Suffers from a renal or hepatic impairment
• Has been treated for scabies by any form of scabies treatment whether prescription, over-the-counter or a home remedy within a month prior to their screening visit
• Had received or used an investigational new drug within the month immediately preceding the screening
• Is receiving any medication likely to mask or modify scabies
• Will not be available for follow up visits
• Has other cutaneous conditions which might be confused with scabies
• Seriously immune suppressed subjects
• Has been previously empaneled in this study

Related Conditions & MeSH terms

• Scabies

Intervention

Drug:
• Permethrin Cream 5%
Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.

Locations

Country	Name	City	State
United States	Universal Biopharma Research Institute Inc.	Dinuba	California
United States	West Houston Clinical Research Service	Houston	Texas
United States	Long Beach Clinical Trials Services, Inc.	Long Beach	California
United States	SouthCoast Research Center, Inc (Clinical Site & Drug Shipment Facility)	Miami	Florida
United States	Havana Research Institute	Pasadena	California

Sponsors (2)

Lead Sponsor	Collaborator
Saptalis Pharmaceuticals LLC	bioRASI, LLC

Country where clinical trial is conducted

United States, 

References & Publications (2)

Goldust M, Babae Nejad S, Rezaee E, Raghifar R. Comparative trial of permethrin 5% versus lindane 1% for the treatment of scabies. J Dermatolog Treat. 2013 Jan 20. [Epub ahead of print] — View Citation

Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005 Oct 19;5:88. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is the proportion of index subjects in the Per Protocol (PP) population in each treatment group with treatment cure when examined at Visit 4 (Day 28 ± 2 Days).	Cure is defined as demonstration of clinical cure (all clinical findings have completely resolved, including inflammatory/non-inflammatory lesions) and microscopic cure (demonstration of the absence of mites, ova, and/or mite feces) on Day 28. Negative microscopy can be declared if no mites, ova, or mite feces is found from a minimum of 3 skin scrapings from previously affected sites.	Day 28 ± 2 Days

External Links

•   Cochrane Review PDF
•   Elimite® FDA prescribing information
•   Mechanism of action
•   Related Info
•   Related Info